Gurusher Panjrath, MD
Advanced Heart Failure and Transplant Cardiology · Washington, DCNPI 1437325883
Payments from drug & device makers
Across 569 payments — averaging $1479.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$270K
- Cvrx, Inc.$247K
- Pfizer$137K
- Ionis Pharmaceuticals, Inc.$51K
- Alnylam Pharmaceuticals Inc.$47K
- United Therapeutics Corporation$26K
- plus $62K from 23 others
Across 1 payment — averaging $750.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$751
What the payments were for
- Consulting fees$192,05145%
- Speaking & faculty fees$166,06539%
- Travel & lodging$40,43810%
- Food & beverage$27,0106%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 2 | $270,195 |
| Cvrx, Inc. | 224 | $246,772 |
| Pfizer | 99 | $137,271 |
| Ionis Pharmaceuticals, Inc. | 11 | $51,319 |
| Alnylam Pharmaceuticals Inc. | 42 | $47,320 |
| United Therapeutics Corporation | 8 | $26,494 |
| Abbott | 59 | $25,958 |
| Bridgebio Pharma, Inc. | 9 | $12,923 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $7,594 |
| American Regent | 1 | $5,686 |
| Boston Scientific | 21 | $5,281 |
| Medtronic(2 entities) | 43 | $2,347 |
| Abiomed | 11 | $967 |
| Amgen | 2 | $335 |
| Edwards Lifesciences | 2 | $276 |
| Novartis | 4 | $163 |
| Akcea Therapeutics, Inc. | 1 | $156 |
| Daxor Corporation | 2 | $155 |
| Scpharmaceuticals Inc. | 5 | $120 |
| AstraZeneca | 5 | $109 |
| Cook Medical LLC | 3 | $65 |
| Bracco Diagnostics Inc. | 2 | $50 |
| Atricure, Inc. | 1 | $45 |
| Angiodynamics, Inc. | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Novo Nordisk | 1 | $34 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Cardiovascular Systems Inc. | 1 | $18 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$206,353
- VYNDAQEL$132,805
- AMVUTTRA$41,026
- Attruby$12,923
- INJECTAFER$5,686
- GENERAL - THERAPIES$3,500
- HeartMate II LVAS$758
- CardioMEMS HF System$713
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$700
- CardioSight$524
- GENERAL TACHY$494
- VYNDAMAX$466
- Claria MRI$435
- HeartMate 3 Left Ventricular Dev$293
- Impella$258
- VIGILANT X4 CRT-D$241
- COBALT DR MRI SURESCAN$238
- VIGILANT$224
- Micra$218
- SAPIEN 3 Ultra RESILIA$199
How this compares
Too few advanced heart failure and transplant cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 42 | $1,467,581 |
| EntrestoSacubitril/Valsartan | 319 | $402,705 |
| JardianceEmpagliflozin | 274 | $314,784 |
| EliquisApixaban | 78 | $84,047 |
| FarxigaDapagliflozin Propanediol | 54 | $40,534 |
| VerquvoVericiguat | 16 | $30,508 |
| OzempicSemaglutide | 23 | $22,363 |
| TrulicityDulaglutide | 16 | $14,433 |
| XareltoRivaroxaban | 20 | $13,280 |
| CorlanorIvabradine Hcl | 17 | $10,760 |
| Metoprolol Succinate | 237 | $3,614 |
| Bumetanide | 64 | $2,511 |
| Spironolactone | 275 | $2,342 |
| Eplerenone | 20 | $1,754 |
| Midodrine Hcl | 16 | $1,389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $137,271 | $1,551,628120 claims |
| NovartisEntresto | $163 | $402,705319 claims |
| AstraZenecaFarxiga | $109 | $40,53454 claims |
| MerckVerquvo | $270,195 | $30,50816 claims |
| Novo NordiskOzempic | $34 | $22,36323 claims |
| AmgenCorlanor | $335 | $10,76017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Washington
- Farooq SheikhWashington$1.3M
- Shaline RaoWashington$194K
- Mrinalini KrishnanWashington$111K
- Mark HofmeyerWashington$46K
- Phillip LamWashington$39K
- Samer NajjarWashington$37K
- Tania VoraWashington$15K
- Ul WeenaWashington$4K
- Ahmed KhanWashington$957
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.